MedTrace Logo

South Australian Meningococcal B Vaccine Herd Immunity Study

NCT03089086 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34489

Last updated 2019-07-02

No results posted yet for this study

Summary

To estimate the effect on carriage, all year 10, 11, and 12 students will be offered 4CMenB vaccination in South Australia through schools over the study period with 50% of the students enrolled receiving the vaccine in 2017 and 50% in 2018. In year 10 and 11 students, posterior pharyngeal swabs will be obtained at baseline and 12 months post baseline to estimate the difference in carriage prevalence of all genogroups of N. meningitidis between vaccinated and unvaccinated participants.

Conditions

  • Meningococcal Disease

Interventions

BIOLOGICAL

Licensed 4CMenB vaccine

Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to \<3 months apart in adolescents.

Sponsors & Collaborators

  • SA Health

    collaborator OTHER

  • University of Adelaide

    lead OTHER

Principal Investigators

  • Helen Marshall · University of Adelaide

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2018-07-13
Completion
2018-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03089086 on ClinicalTrials.gov